Bryan Johnson’s Biomarkers: The Science and Limits of Biological Age

Niko Hems’ 13 August review examines Bryan Johnson’s biomarker program and its limits. Hems describes the protocol as an instrumented n=1 that measures blood markers, imaging, functional tests, and epigenetic clocks. He accepts that the volume of measurement can support tracking, but separates data collection from clinical meaning. The review identifies 3 main problems: no control group, confounding from changing diet, exercise, sleep, supplements, and other therapies together, and reliance on surrogate endpoints. Hems argues that a lower epigenetic age or slower pace of aging is not proof of fewer heart attacks, less cancer, or longer life. He treats grip strength and VO2 max as closer to functional outcomes than biological-age scores, while still presenting them as risk markers rather than randomized evidence. The review recommends medical interpretation and baseline assessment instead of self-quantification alone. It is a named critical response, not a new trial and not an independent audit of Johnson’s raw records. The article was updated on 13 August 2026, which is the date used here. It does not test any Blueprint ingredient, does not report a human RCT of the stack, and gives no basis for an evidence-grade upgrade. Its main value is methodological: it states plainly what the public data cannot identify.

Johnson's Blueprint project has raised awareness for preventive health and the value of data.